Literature DB >> 11684680

Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells.

Fan Yeung1, Wai K Law, Ching-Hua Yeh, Jennifer J Westendorf, Ye Zhang, Ruoxiang Wang, Chinghai Kao, Leland W K Chung.   

Abstract

Osteocalcin (OC) is a small (6 kDa) polypeptide whose expression was thought to be limited to mature osteoblasts. The discovery of OC expression in prostate cancer specimens led us to study the regulation of OC gene in androgen-independent metastatic human prostate PC3 cells. An 800-bp human OC (hOC) promoter-luciferase construct exhibited strong basal and vitamin D-induced activity in OC-positive human prostate and osteosarcoma cell lines. Through deletion analysis of the hOC promoter, the functional hierarchy of the cis-acting elements, OSE1, OSE2, and AP-1/VDRE, was established in PC3 cells (OSE1 > AP-1/VDRE > OSE2). By juxtaposing dimers of these 3 cis-elements, we produced a minimal hOC promoter capable of displaying high tissue specific activity in prostate cancer cells. Our study demonstrated three groups of transcription factors, Runx2, JunD/Fra-2, and Sp1, responsible for the high hOC promoter activity in PC3 cells by binding to the OSE2, AP-1/VDRE, and OSE1 elements, respectively. Among the three groups of transcription factors, the expression levels of Runx2 and Fra-2 are higher in the OC-positive PC3 cells and osteoblasts, compared with the OC-negative LNCaP cells. Interestingly, unlike the mouse OC promoter, the OSE1 site in hOC promoter is regulated by members of Sp1 family instead of the osteoblast-specific factor Osf1. The molecular basis for androgen-independent prostate cancer cells behaving like mature osteoblasts may be explained by the interplay and coordination of these transcription factors under the tight regulation of autocrine and paracrine mediators.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684680     DOI: 10.1074/jbc.M105947200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

Authors:  Marxa L Figueiredo; Makoto Sato; Mai Johnson; Lily Wu
Journal:  Future Oncol       Date:  2006-06       Impact factor: 3.404

Review 2.  Advances in preclinical investigation of prostate cancer gene therapy.

Authors:  Marxa L Figueiredo; Chinghai Kao; Lily Wu
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

3.  In vivo bioluminescence imaging of cell differentiation in biomaterials: a platform for scaffold development.

Authors:  Juli R Bagó; Elisabeth Aguilar; Maria Alieva; Carolina Soler-Botija; Olaia F Vila; Silvia Claros; José A Andrades; José Becerra; Nuria Rubio; Jerónimo Blanco
Journal:  Tissue Eng Part A       Date:  2012-12-21       Impact factor: 3.845

4.  The transcriptional activity of osterix requires the recruitment of Sp1 to the osteocalcin proximal promoter.

Authors:  Corinne Niger; Florence Lima; David J Yoo; Rishi R Gupta; Atum M Buo; Carla Hebert; Joseph P Stains
Journal:  Bone       Date:  2011-07-28       Impact factor: 4.398

5.  A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone.

Authors:  Parisa Hesami; Boris M Holzapfel; Anna Taubenberger; Martine Roudier; Ladan Fazli; Shirly Sieh; Laure Thibaudeau; Laura S Gregory; Dietmar W Hutmacher; Judith A Clements
Journal:  Clin Exp Metastasis       Date:  2014-02-08       Impact factor: 5.150

6.  PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.

Authors:  Yinhui Yang; Yang Bai; Yundong He; Yu Zhao; Jiaxiang Chen; Linlin Ma; Yunqian Pan; Michael Hinten; Jun Zhang; R Jeffrey Karnes; Manish Kohli; Jennifer J Westendorf; Benyi Li; Runzhi Zhu; Haojie Huang; Wanhai Xu
Journal:  Clin Cancer Res       Date:  2017-11-22       Impact factor: 12.531

7.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

8.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

9.  The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.

Authors:  Nader Al Nakouzi; Olivia Bawa; Alain Le Pape; Stéphanie Lerondel; Catherine Gaudin; Paule Opolon; Patrick Gonin; Karim Fizazi; Anne Chauchereau
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

10.  Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA.

Authors:  Sanjeev K Baniwal; Omar Khalid; Donna Sir; Grant Buchanan; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Endocrinol       Date:  2009-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.